36.76USD+0.19%Mkt Cap: 2.32B USDP/E: —Last update: 2026-06-01
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.32B USD
Enterprise Value2.18B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-229.97M USD
Revenue/Share—
Last Price36.76 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS50015M1099
Valuation
P/E (Trailing)—
P/E (Forward)-11.78
PEG—
EV/EBITDA-9.94
EV/Revenue—
P/S—
P/B20.30
EPS (TTM)-4.17
EPS (Forward)-3.12
52W Range
3.26075% of range47.84
52W High47.84 USD
52W Low3.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-146.12%
ROA-65.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-136.01M USD
CapEx (TTM)506.00K USD
FCF Margin—
FCF Yield-2.25%
Net Debt-113.54M USD
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity0.38
Current Ratio3.54
Quick Ratio3.42
Book Value/Sh1.808 USD
Cash/Share2.715 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)62.67 USD
Target Range56.00 USD – 80.00 USD
# Analysts6
Ownership
Shares Out.62.58M
Float39.28M
Insiders5.18%
Institutions99.56%
Short Interest
Short Ratio16.2d
Short % Float25.87%
Short % Out.16.31%
Shares Short10.20M
Short (prev mo.)10.32M
Technical
SMA 5038.67 (-4.9%)
SMA 20024.56 (+49.7%)
Beta2.32
S&P 52W Chg27.94%
Avg Vol (30d)550.70K
Avg Vol (10d)618.73K
Technical Indicators
RSI (14)44.2
MACD-1.2095
MACD Signal-0.8136
MACD Hist.-0.3959
BB Upper45.62 USD
BB Middle38.91 USD
BB Lower32.20 USD
BB Width34.50%
ATR (14)2.704 USD
Vol Ratio (20d)0.40x